Tempus AI
- Market cap
- 12.69B
- P/E (TTM)i
- -48.85
- P/Bi
- 28.53
- EPSi
- -1.41
- Div yieldi
- 0.00%
- 52W posi
- 52%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Health Information Services
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Tempus AI (TEM) | 12.69B | -48.85 | 28.53 | 0.00% |
| Veeva Systems (VEEV) | 45.74B | 46.31 | 6.15 | 0.00% |
| BrightSpring Health Services (BTSG) | 12.62B | 38.67 | 6.16 | 0.00% |
| Hinge Health (HNGE) | 7.90B | 73.14 | 22.93 | 0.00% |
| HealthEquity (HQY) | 7.60B | 33.18 | 3.82 | 0.00% |
| Waystar Holding (WAY) | 4.94B | 36.81 | 1.24 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 6.2% below Morningstar's fair value estimate.
Fair value
Tempus AI Inc receives a 2-star quantitative star rating, indicating our belief that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 10% premium over our quantitative fair value estimate of $74.68 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.
The company's valuation metrics weaken our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to EBITDA ratio sits in the top 1% globally. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. We believe this is a sign that shares could be expensive.
The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's enterprise value to free cash flow ratio of 476.4, for example, lies in the top 10% compared with peers globally. This suggests limited cash flow is available for reinvestment or return to shareholders, which further promotes our unfavorable price/fair value ratio.
Economic moat
The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-10-08 07:30:12 · For reference only, not investment advice and not tailored to your situation.